Erectile dysfunction is one of the most common conditions in the westernised world, affecting between 10 and 40% of men at some time. But only a fraction of the 90 million men affected worldwide are currently receiving treatment.
Revolutionary developments are changing the way in which erectile dysfunction is treated and the erectile dysfunction product market is expected to grow exponentially over the next few years.
Scrip Reports brings you a complete overview of this subject. This new Industry Alert provides you with a clear overview of a market undergoing significant development. This timely report will enable you to review established and new products and evaluate the treatment market and companies involved.
CONTENTS
LIST OF TABLES
LIST OF FIGURES
EXECUTIVE SUMMARY
SCOPE AND METHODOLOGY
CHAPTER 1 ERECTILE DYSFUNCTION
1.1 Introduction and definition
1.2 The scale of the problem - incidence data
1.3 The impact of impotence
CHAPTER 2 WHAT GOES WRONG?
2.1 Mechanism of erection
2.2 Causes of ED
2.3 Diagnosis of ED
CHAPTER 3 CURRENT TREATMENT OF ERECTILE DYSFUNCTION
3.1 A brief history of the treatment of ED
3.2 US clinical guidelines (1996 AUA report)
3.3 Treatment of ED in Europe
3.4 Current drug use in ED
3.5 The importance of counselling
3.6 Current patient population just 'the tip of the iceberg'?
CHAPTER 4 DRUGS MARKETED FOR USE IN ED
4.1 Pharmacia & Upjohn's Caverject (ic alprostadil)
4.2 Schwarz Pharma's Viridal/Edex (ic alprostadil alphadex)
4.3 Vivus's MUSE (intraurethral alprostadil)
4.4 Fournier's Erecnos (ic moxisylyte)
4.5 Byk Nederland's Androskat
CHAPTER 5 DRUGS UNDER DEVELOPMENT FOR ED
5.1 Senetek's Invicorp (ic VIP with phentolamine)
5.2 Pfizer's Viagra (oral sildenafil)
5.3 Zonagen/Schering-Plough's Vasomax (oral phentolamine)
5.4 TAP's Spontane (sublingual apomorphine)
5.5 Harvard Scientific Corporation's intraurethral alprostadil
5.6 NexMed's Alprox-TD (alprostadil cream)
5.7 MacroChem's alprostadil cream
5.8 Futura Medical Ltd's Med 900 (nitroglycerin cream)
5.9 HealthScene's HSI-600
5.10 NitroMed's NMI-102
5.11 Other products that have been under investigation
CHAPTER 6 THE ED PHARMACEUTICAL MARKET
6.2 Some views of the future
6.3 Market set for explosion
6.4 Female sexual dysfunction - a further market opportunity?
CHAPTER 7 COMPANY PROFILES
7.2 Byk Nederland bv
7.3 Fournier
7.4 Futura Medica
7.5 Harvard Scientific Corporation
7.6 Janssen Pharmaceutica
7.7 NexMed
7.8 Pfizer
7.9 Pharmacia & Upjohn
7.10 Schering-Plough
7.11 Schwarz Pharma
7.12 Senetek
7.13 TAP - Takeda Abbott Pharmaceuticals Inc
7.14 Vivus
7.15 Zonagen Inc
REFERENCES
USEFUL CONTACTS
FORTHCOMING EVENTS IN THE ED FIELD
LIST OF TABLES
Table 3.1 Methods of treating ED in Europe
Table 3.2 Preferred product for self-injection
Table 4.3 Efficacy of moxisylyte, alprostadil and papaverine compared
Table 5.1 Adverse events experienced by men using Invicorp or placebo
Table 5.2 Adverse events recorded during the Pfizer UK trial of sildenafil
Table 5.3 Adverse events in a six-month placebo-controlled trial of sildenafil
Table 5.4 Efficacy of sildenafil in cases of severe ED
LIST OF FIGURES
Figure 2.1 Cross section of the penis
Figure 2.2 Transverse section of the penis
Figure 4.1 The Buckling test
PUBLISHED: MARCH 1998
REF: BS942E
PAGES: 118
PRICE: £143/$300/¥35,000
© PJB Publications Ltd. 2001 All rights reserved. |